Reply: Ex vivo SOCS3 gene responsiveness to alarmins in eosinophils of mepolizumab-treated patients is as yet of unknown biological significance

Eur Respir J. 2022 Jul 21;60(1):2200981. doi: 10.1183/13993003.00981-2022. Print 2022 Jul.

Glenn Van Hulst^{1

2}, Joseph Jorssen^{1

2}, Nathalie Jacobs¹, Monique Henket³, Renaud Louis³, Florence Schleich³, Fabrice Bureau^{1

4

2}, Christophe J Desmet^{5

3

2}

¹ Laboratory of Cellular and Molecular Immunology, GIGA Institute and Faculty of Veterinary Medicine, Liege University, Liege, Belgium.
² Equal contributors.
³ Laboratory of Pneumology, GIGA Institute, Faculty of Medicine and University Hospital Center, Liege University, Liege, Belgium.
⁴ Walloon Excellence in Life Sciences and Biotechnology (Welbio), Wavres, Belgium.
⁵ Laboratory of Cellular and Molecular Immunology, GIGA Institute and Faculty of Veterinary Medicine, Liege University, Liege, Belgium christophe.desmet@uliege.be.

No abstract available

Publication types